# IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome

Study · id `cardio:ct-nct06451198` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06451198](<https://clinicaltrials.gov/study/NCT06451198>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06451198

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2846 participants.

## Technical summary

Registry record NCT06451198. Randomized; single masking; primary purpose treatment. Start 2025-05-19 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2846 participants (planned count; ClinicalTrials.gov record NCT06451198, source copy `cardio:ctgov-nct06451198-2026-03-12`, retrieved 2026-10-26)
- Started: 2025-05-19 (actual) (ClinicalTrials.gov record NCT06451198, source copy `cardio:ctgov-nct06451198-2026-03-12`, retrieved 2026-10-26)
- Primary completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT06451198, source copy `cardio:ctgov-nct06451198-2026-03-12`, retrieved 2026-10-26)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT06451198, source copy `cardio:ctgov-nct06451198-2026-03-12`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06451198, source copy `cardio:ctgov-nct06451198-2026-03-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06451198-2026-03-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
- Acronym: OPTION2
- Condition: Coronary Artery Disease
- Condition: Antiplatelet Drugs
- Intervention (Drug): Indobufen
- Intervention (Drug): Aspirin
- Intervention (Drug): Ticagrelor
- Lead sponsor: Shanghai Zhongshan Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry lists this organization as the lead sponsor: Shanghai Zhongshan Hospital (`cardio:org-shanghai-zhongshan-hospital`)

## Provenance

Content hash: f54195c6734a7373eb2f1ce8241d21cfff69661da7a022159af3bd68737e69ce
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
